Diplopia
Myasthenia Gravis

Bringing Ocular Myasthenia Gravis Into Focus: From Diagnostic Dilemmas to Targeted Therapeutics

Fluctuating ptosis and diplopia are frequently the earliest manifestations of myasthenia gravis (MG), often resulting in an initial diagnosis of ocular MG (oMG), with some patients progressing to generalized MG (gMG) over time. Accurately identifying oMG remains challenging due to broad differential diagnoses and the inconsistent application of diagnostic tools across specialties.Furthermore, managing oMG currently relies heavily on conventional immunosuppressive therapies, with much of the evidence extrapolated from gMG data, leaving patients facing variable treatment efficacy, meaningful toxicity risks, and persistent unmet needs.Join two leading experts as they address key diagnostic challenges and evolving treatment considerations in oMG. Gain practical, evidence-based insights to help you:Overcome clinical uncertainty and confidently apply diagnostic tools to accurately identify oMGIdentify high-risk patients and implement structured monitoring for progression from oMG to gMGEvaluate the limitations and patient burden associated with conventional management strategiesAssess the mechanisms of action and emerging clinical evidence for targeted therapies and their potential role in the evolving oMG treatment landscape.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

No specific specialties targeted.

Pricing

Free

Reported to ACCME by the provider

Enduring / On-demand
Credit · Up to 0.75 credits
Commercial Support

Available from

Oct 26, 2026
Last day to claim credit

Oct 26, 2027 1 year left

Bringing Ocular Myasthenia Gravis Into Focus: From Diagnostic Dilemmas to Targeted Therapeutics

Related courses

More from PRIME Education, Inc. (PRIME®)